5 / 21
Page 51
Notes:
allied
academies
Microbiology: Current Research 2017 | Volume 1, Issue 2
Joint Conference
GLOBAL APPLIED MICROBIOLOGY CONFERENCE
MICROBIAL & BIOCHEMICAL RESEARCH AND TECHNOLOGIES
October 18-19, 2017
Toronto, Canada
International Congress on
&
In vitro
activities of six antifungal drugs against
Candida glabrata
isolates: An emerging pathogen
Nasrin Amirrajab
1, 2
, Tahereh Shokohi
2
, Hamid Badali
2,
Mojtaba Didehdar
3
, Mohammad Hosein Afsarian
4,
Rasoul Mohammadi
5
and
Nazanin Lotfi
2
1
Ahvaz Jundishapur University of Medical Sciences, Iran
2
Mazandaran University of Medical Sciences, Iran
3
Arak University of Medical Sciences, Iran
4
Fasa University of Medical Sciences Iran
5
Isfahan University of Medical Sciences, Iran
Background:
Candida glabrata
is pathogenic yeast with several
unique biological features and associated with an increased
incidence rate of candidiasis. It exhibits a great degree of
variation in its pathogenicity and antifungal susceptibility.
Objectives:
The aim of the present study was to evaluate the
in vitro
antifungal susceptibilities of the following six antifungal
drugs against clinical
C. glabrata
strains: amphotericin B (AmB),
ketoconazole (KTZ), fluconazole (FCZ), itraconazole (ITZ),
voriconazole (VCZ), and caspofungin (CASP).
Materials & Methods:
Forty clinical
C. glabrata
strains were
investigated using DNA sequencing. The
in vitro
antifungal
susceptibility was determined as described in clinical laboratory
standard institute (CLSI) documents (M27-A3 and M27-S4).
Results:
The sequence analysis of the isolate confirmed as
C.
glabrata
and deposited on NCBI GenBank under the accession
number no. KT763084-KT763123. The geometric mean MICs
against all the tested strains were as follows, in increasing order:
CASP (0.17 g/mL), VCZ (0.67 g/mL), AmB (1.1 g/mL), ITZ (1.82 g/
mL), KTZ (1.85 g/mL), and FCZ (6.7 g/mL). The resistance rates
of the isolates to CASP, FCZ, ITZ, VZ, KTZ, and AmB were 5%,
10%, 72.5%, 37.5%, 47.5%, and 27.5%, respectively.
Discussion:
The intrinsically low susceptibility of C. glabrata,
an emerging opportunistic fungal pathogen, to azole
antifungals has made its treatment challenging, and infection
is accompanied by frequent relapse and failure. The findings
indicate that the decreased susceptibility of Candida to azole
agents may contribute to the increased proportion of infections
caused by these species. Caution is thus recommended with
CASP therapy for
C. glabrata
infections when azole resistance
is predicted. The resistance of
C. glabrata
clinical isolates to
both azoles and echinocandins has emerged over time. This is
problematic, owing to its treatment limitations.
Conclusion:
These findings confirm that CASP, compared to the
other antifungals, is the potent agent for treating candidiasis
caused by
C. glabrata
. However, the clinical efficacy of these
novel antifungals remains to be determined.
Speaker Biography
Nasrin Amirrajab is working in Ahvaz Jundishapur University of Medical Sciences, Iran.
She is from Iran.
e:
n_amirrajab@yahoo.com